BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C. Wainwright ...
In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...
The BioMarin Pharmaceutical Inc. acquisition of Amicus Therapeutics, Inc. will likely be beneficial and accretive for both ...
BioMarin adds scale of operations, including global commercial footprint and in-house manufacturing capabilities for rare ...
BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...
Leerink analyst Joseph Schwartz downgraded Amicus (FOLD) to Market Perform from Outperform with a price target of $14.50, down from $17, following ...
Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an ...
BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.
Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...
Amicus has endured a tough few years of pipeline flops and a roller coaster stock ride, but now it’s riding the special purpose acquisition company wave, spinning off its gene therapy unit in a $600 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback